A Randomized, Placebo Controlled Clinical Trial to Evaluate the Effects of Simvastatin Treatment on Measurements of Lipidomic Biomarkers in Men With Dyslipidemia.
Phase of Trial: Phase I
Latest Information Update: 19 Nov 2013
At a glance
- Drugs Simvastatin (Primary)
- Indications Dyslipidaemias
- Focus Biomarker; Pharmacodynamics
- Sponsors Merck & Co
- 17 Feb 2012 Actual patient number changed from 40 to 31 as reported by ClinicalTrials.gov.
- 09 Sep 2010 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
- 31 Oct 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.